NEUROCRINE BIOSCIENCES INC (NBIX): Results of Operations and Financial Condition
NEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-2026xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to
How this was made
The 30-second read
Why it matters
The key tradable inputs are the raised INGREZZA full-year net sales guidance range and the reported Q2 revenue growth, alongside segment drivers and acquisition-related accounting impacts.
Market read
Raised guidance and strong Q2 growth are likely to drive immediate repricing of 2026 revenue expectations for NBIX.
What to watch
GAAP operating expenses include acquisition-related items; traders should separate one-time Soleno costs from underlying expense growth when assessing margin durability.
Background
This is Neurocrine Biosciences’ SEC 8-K reporting Q2 2026 results and financial condition, including updated full-year guidance and post-acquisition updates from Soleno Therapeutics.
Ticker impact
Neurocrine raised 2026 INGREZZA net sales guidance to $2.825B-$2.875B and reported Q2 revenue up 39% YoY to $959M.
Near-term upside bias as traders reprice 2026 revenue expectations; follow-through depends on whether cash balance and expense trajectory remain manageable post-Soleno.
The filing is a primary earnings and guidance disclosure with specific updated ranges, and it includes segment-level drivers (INGREZZA TRx/NRx growth, CRENESSITY demand, VYKAT XR contribution from Soleno).
Market effects
Reinforces demand strength in neuropsychiatric and rare-disease commercial biopharma, potentially supporting sentiment for profitable specialty peers.
Limited direct regional spillover; primarily US biotech sentiment.
Modest global relevance given company-specific guidance and acquisition integration details.
Counterpoint
Cash and marketable securities fell to about $482M at June 30, which could raise concerns about near-term liquidity despite the new $1.0B revolver.
Key entities
- issuerNeurocrine Biosciences, Inc.
Reports Q2 2026 financial results, raises 2026 INGREZZA guidance, and provides updates tied to Soleno acquisition and clinical programs.
- productINGREZZA (valbenazine)
Core revenue driver; Q2 net product sales grew 15% YoY and full-year 2026 guidance was raised.
- productCRENESSITY (crinecerfont)
Rare-disease therapy; Q2 net product sales rose to $184M with strong reimbursement/dispensed prescription demand.
- productVYKAT XR (diazoxide choline)
Contributed $54M in Q2 net product sales from May 18 Soleno acquisition closing; pro-forma full quarter $94M.
- acquisition_targetSoleno Therapeutics
Acquisition completed in May 2026; VYKAT XR included from closing date and acquisition-related expenses noted.
